JACKSONVILLE, FL, Feb. 04, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – mCig, Inc. (MCIG), a vertically integrated company focused on development and commercialization of over the counter, science-driven, botanical nutrigenetics targeting the endocannabinoid system, today announced that its subsidiary (BRRX Clinical) will be launched on Monday, February 10, 2020.Dale Hipes, CEO of BareRoots-Rx Inc., stated: “We believe the launch of the new site will be an opportunity to set our brand apart from the competition. The site will target individual participants, and it will be responsive to the identification ofSEE DETAILS

JACKSONVILLE, FL – (NewMediaWire) – January 27, 2020 – mCig, Inc. (MCIG), a vertically integrated company focused on the development and commercialization of OTC, science-driven, botanical nutrigenetics targeting the endocannabinoid system, today announced the business plan for the nutraceutical joint venture of the Company and Bare Roots, Inc.BRRX Clinical will operate under two divisions, Consumer Products, and Health Care. The Consumer Products Division will operate much as most other CBD product companies, however, the emphasis will be on products with verifiable efficacy and prescribed dosages. As part of this strategy theSEE DETAILS

JACKSONVILLE, FL – (NewMediaWire) – January 23, 2020 – mCig, Inc. (OTCQB:MCIG), vertically integrated company focused on the development and commercialization of OTC, science-driven, botanical nutrigenetics targeting the endocannabinoid system today announced that the nutraceutical joint venture of the Company and BRRx Clinical Inc. is set to move forward with an LOI to supply a national independent compounding pharmacy network. BRRX Clinical will begin releasing the CBD enhanced medical foods/topical applications that are in FDA trials. The products are registered with the International Review Board. The first of these offerings willSEE DETAILS

JACKSONVILLE, FL – (NewMediaWire) – January 21, 2020 – mCig, Inc. (OTCQB:MCIG), a vertically integrated company focused on the development and commercialization of over the counter, science-driven, botanical nutrigenetics, that target the endocannabinoid system, announces today that the company’s subsidiary, BareRoots Rx, is launching the Co-branding deal with the Tucson Sugar Skulls of the IFL as their exclusive CBD sports partner.Dale Hipes, CEO of BareRoots, says: “This is a great opportunity for BareRoots to help bring CBD to households in the Arizona region and Nationally throughout the US. The Tucson SugarSkullsSEE DETAILS

JACKSONVILLE, FL – (NewMediaWire) – January 17, 2020 – mCig, Inc. (OTCQB:MCIG), vertically integrated company focused on the development and commercialization of over the counter, science-driven, botanical nutrigenetics that target the endocannabinoid system, today announced that the company’s CBD consumer division has agreements to commence this quarter.MCIG Inc. subsidiary, BareRoots Rx Inc., the consumer products division, has entered into an agreement to distribute 10,000 monthly boxes of the COMPANY’S PROPRIETARY CBD-BASED PRODUCTS to select tribal communities. The company anticipates revenue of approximately $1.1 Mil in its first year of operation underSEE DETAILS

JACKSONVILLE, FL – (NewMediaWire) – January 13, 2020 – mCig, Inc. (OTCQB: MCIG) today announced that its subsidiary BareRoots has launched a completely redesigned website (www.bareroots-rx.com) and the rebranding of its globally recognized hemp-derived cannabidiol (CBD) products. Through the recently created consumer-driven website, the Company hopes that it’s visitors, customers, and consumers will find the website much easier to use. The navigation has been designed to be much simple, products become very easy to access, and add to cart and a well educative CBD section has been added to match consumer’s lifestyle.SEE DETAILS

JACKSONVILLE, FL – (NewMediaWire) – December 12, 2019 – mCig, Inc. (OTCQB:MCIG), a vertically integrated company focused on the development and commercialization of OTC, science-driven, botanical nutrigenetics that target the endocannabinoid system, and Bareroots RX Inc. are expanding their activities collectively in the production and development of lifestyle improvement and health care enhancing CBD (cannabinoid) based products. “As we look forward to 2020, our focus has shifted to a healthcare and medically driven CBD botanical products. We’re committed to adapting to the changing cannabis market in order to maximize ourSEE DETAILS